Key result
Nasal adamantinoma-like Ewing sarcoma case reveals a previously unreported NRAS Q61R mutation.
Why the study?
Adamantinoma-like Ewing sarcoma demonstrates morphologic and immunohistochemical features distinct from conventional Ewing sarcoma, prompting reporting of rare clinicopathological presentations and novel mutations.
Reports a novel NRAS Q61R mutation in a rare case of Adamantinoma-like Ewing sarcoma of the nasal septum.
Answers are grounded in this paper and cite their sources.
Supports expanded genetic profiling in rare Ewing sarcoma variants; leaves open the mutation's clinical implications.
Adamantinoma-like Ewing sarcoma (ALES) is a rare malignant neoplasm currently classified as a subtype of Ewing sarcoma (ES) and is similarly molecularly defined by a FET-ETS translocation. However, ALES demonstrates some morphologic and immunohistochemical features distinct from conventional ES. In this case report, we present the clinico-pathological features of a case of ALES in the nasal septum of a 75-year-old lady, with a hitherto unreported NRAS Q61R mutation. Further studies are required to investigate the prevalence and clinical significance of the NRAS Q61R mutation in ALES.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2025) studied this question. A case of adamantinoma-like Ewing sarcoma in the nasal cavity exhibited a previously unreported NRAS Q61R mutation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: